Anti-IL17RA Neutralizing Antibody (V3S-0622-YC1899) (CAT#: V3S-0622-YC1899)

Figure 1 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in ELISA

ELISA analysis of V3S-0622-YC1899 was performed by coating with Human IL17RA Protein (His Tag). Then blocked with BSA and incubated with V3S-0622-YC1899. The HRP-conjugated goat anti-human IgG as a secondary antibody (1:6000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 2 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in WB

Western blot analysis of V3S-0622-YC1899 was performed by loading Human IL17RA Protein (His Tag) in reduced condition Lane 1 (Non-reducing antigen, 0.5 μg) and Lane 2 (Reducing antigen, 0.5 μg) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC1899 (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1:6000). Chemiluminescent detection was performed.

Figure 3 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in SDS-PAGE

SDS-PAGE analysis of V3S-0622-YC1899 in non-reduced (lane 1) and β-mercaptoethanol-reduced (lane 2) conditions. Gel stained for 30 minutes with Coomassie Blue. As a result of different β-mercaptoethanol-reduced proteins (Heavy chain and Light chain) migrate as about 50 kDa and 25 kDa, respectively. And non-reduced protein migrates as 130-180 kDa.

Figure 4 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in SEC-HPLC

The purity of V3S-0622-YC1899 was greater than 95% as determined by SEC-HPLC.

Column: 3 µm, 7.8 x 300 nm
Mobile phase: 150 mM Sodium Phosphate Buffer, pH 7.0
Detection: UV 280 nm
Injection: 10 µl

Figure 5 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in ELISA

ELISA analysis of V3S-0622-YC1899 was performed by coating with Human IL17RA Protein (His Tag). Then blocked with BSA and incubated with V3S-0622-YC1899. The HRP-conjugated goat anti-human IgG as a secondary antibody (1: 5000). Detection was performed using TMB substrate and stopped with sulfuric acid. The absorbances were read on a spectrophotometer at 450 nm.

Figure 6 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in WB

Western blot analysis of V3S-0622-YC1899 was performed by loading Human IL17RA Protein (His Tag) in reduced condition Lane 1, Lane 2 and Lane 3 (0.1 μg, 0.3 μg and 0.6 μg respectively) onto a 12% Tris-HCl polyacrylamide gel. Proteins were transferred to a CN membrane and blocked with 5% skim milk for at least one hour. Membranes were probed with V3S-0622-YC1899 (2 μg/mL) and HRP-conjugated goat anti-human IgG as a secondary antibody (1: 6000). Chemiluminescent detection was performed.

Figure 7 Anti-Human IL17RA Monoclonal Antibody (V3S-0622-YC1899) in DB

Dot Blot analysis of V3S-0622-YC1899 was performed by coating with Human IL17RA Protein (His Tag).

V3S-0622-YC1899 incubation concentration: 2 μg/mL.
HRP goat anti-human IgG as a secondary antibody (1: 6000)

NC: Negative control PC: Positive control